Market Place
Sourcing Support
Erasca Reports Momentum For Naporafenib And RAS Franchise
24 Oct 2024 //
GLOBENEWSWIRE
Erasca To Present SEACRAFT-1 Phase 1 Data At EORTC Symposium
25 Sep 2024 //
GLOBENEWSWIRE
Erasca to Present at Upcoming Investor Conferences in September
29 Aug 2024 //
GLOBENEWSWIRE
Erasca Reports Second Quarter 2024 Business Updates and Financial Results
12 Aug 2024 //
GLOBENEWSWIRE
Erasca Initiates SEACRAFT-2 Phase 3 Trial For Naporafenib InMutant Melanoma
18 Jun 2024 //
GLOBENEWSWIRE
Erasca to Present at Upcoming Investor Conferences in June
29 May 2024 //
GLOBENEWSWIRE
Erasca Announces Common Stock Offering Close, Option Exercise
21 May 2024 //
GLOBENEWSWIRE
Erasca restructures; Novartis moves to complete MorphoSys deal
17 May 2024 //
BIOPHARMADIVE
Erasca Announces Pricing of Underwritten Offering of Common Stock
16 May 2024 //
GLOBENEWSWIRE
Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise
16 May 2024 //
GLOBENEWSWIRE
Erasca Reports First Quarter 2024 Business Updates and Financial Results
08 May 2024 //
GLOBENEWSWIRE
Erasca to Present at the Bank of America Health Care Conference
07 May 2024 //
GLOBENEWSWIRE
Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting
24 Apr 2024 //
GLOBENEWSWIRE
Erasca Reports Fourth Quarter 2023 and Full Year 2023 Financial Results
27 Mar 2024 //
GLOBENEWSWIRE
Erasca Announces $45 Million Oversubscribed Private Placement Financing
27 Mar 2024 //
GLOBENEWSWIRE
Erasca Announces Two Trial Collaboration and Supply Agreements for Trametinib
14 Feb 2024 //
GLOBENEWSWIRE
Erasca to Present at the Guggenheim Talks 6th Annual Biotechnology Conference
01 Feb 2024 //
GLOBENEWSWIRE
Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Jan 2024 //
GLOBENEWSWIRE
Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib
11 Dec 2023 //
GLOBENEWSWIRE
Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs
28 Nov 2023 //
GLOBENEWSWIRE
Erasca Reports Third Quarter 2023 Financial Results and Business Updates
09 Nov 2023 //
GLOBENEWSWIRE
Erasca to Present at Upcoming Investor Conferences in November
08 Nov 2023 //
GLOBENEWSWIRE
Erasca to Present at the Cantor Global Healthcare Conference
19 Sep 2023 //
GLOBENEWSWIRE
Erasca to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
05 Sep 2023 //
GLOBENEWSWIRE
Erasca Doses First Patient SEACRAFT-1 Ph 1b Trial Naporafenib Plus Trametinib
29 Aug 2023 //
GLOBENEWSWIRE
Erasca Reports Second Quarter 2023 Financial Results and Business Updates
10 Aug 2023 //
GLOBENEWSWIRE
FDA Grants Orphan Drug Designation to ERAS-801 for Malignant Glioma
23 Jun 2023 //
ONCOLIVE
Erasca Granted FDA Orphan Desig for CNS-Penetrant EGFR Inhibitor ERAS-801
22 Jun 2023 //
GLOBENEWSWIRE
Erasca erases part of pipeline after revealing mixed cancer data
06 Jun 2023 //
FIERCE BIOTECH
Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007
05 Jun 2023 //
GLOBENEWSWIRE
Erasca to Present at Upcoming Investor Conferences
01 Jun 2023 //
GLOBENEWSWIRE
Erasca to Host Event on Pipeline Updates with a Focus on ERAS-007 ERK Inhibitor
31 May 2023 //
GLOBENEWSWIRE
Erasca to Present Promising Preliminary HERKULES-3 Phase 1b Data
25 May 2023 //
GLOBENEWSWIRE
Erasca Further Strengthens Business Leadership with Two Key Promotions
16 May 2023 //
GLOBENEWSWIRE
Erasca Reports First Quarter 2023 Financial Results and Business Updates
15 May 2023 //
GLOBENEWSWIRE
Erasca to Present at the Bank of America Securities 2023 Health Care Conference
02 May 2023 //
GLOBENEWSWIRE
Erasca Granted FDA Fast Track Designation for CNS EGFR Inhibitor ERAS-801
01 May 2023 //
GLOBENEWSWIRE
Erasca Announces Two Poster Presentations at the 2023 ASCO Annual Meeting
26 Apr 2023 //
GLOBENEWSWIRE
Erasca Announces Publication of Promising Clinical Data Naporafenib
25 Apr 2023 //
GLOBENEWSWIRE
Erasca Presents Promising Initial Ph1b Dose Data from FLAGSHP-1 for ERAS-601
18 Apr 2023 //
GLOBENEWSWIRE
Erasca Strengthens Clinical and Regulatory Leadership with Two Key Appointments
10 Apr 2023 //
GLOBENEWSWIRE
Erasca Reports Fourth Quarter 2022 & 2022 FYR and Business Updates
23 Mar 2023 //
GLOBENEWSWIRE
Erasca Announces Poster Presentation at the 2023 AACR Annual Meeting
14 Mar 2023 //
GLOBENEWSWIRE
Erasca to Present at the Guggenheim Oncology Conference 2023
01 Feb 2023 //
GLOBENEWSWIRE
Erasca to Present at the 41st Annual J.P. Morgan Healthcare Conference
04 Jan 2023 //
GLOBENEWSWIRE
Erasca Announces First Patient Dosed in HERKULES-1 Ph1b Trial ERAS-007
20 Dec 2022 //
GLOBENEWSWIRE
Erasca Announces FDA Clearance of IND for KRAS G12C Inhibitor ERAS-3490
13 Dec 2022 //
GLOBENEWSWIRE
Erasca Announces Pricing of Underwritten Offering of Common Stock
09 Dec 2022 //
GLOBENEWSWIRE
Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib
09 Dec 2022 //
GLOBENEWSWIRE
Erasca delves further into RAS/MAPK with Novartis drug, prices $100M offering
09 Dec 2022 //
ENDPTS
Erasca slides a Novartis melanoma med into pipeline for $20M
09 Dec 2022 //
FIERCEBIOTECH
Erasca Announces Trial Collabo & Supply Agreement Pierre Fabre ERAS-007
30 Nov 2022 //
GLOBENEWSWIRE
Erasca to Present at Upcoming Investor Conferences
22 Nov 2022 //
GLOBENEWSWIRE
Erasca Reports Third Quarter 2022 Financial Results and Business Updates
09 Nov 2022 //
GLOBENEWSWIRE
Erasca Announces Trial Collaboration with Pfizer to Evaluate ERAS-007
20 Oct 2022 //
GLOBENEWSWIRE
Erasca Announces Four Poster Presentations at the Upcoming 34th EORTC-NCI-AACR
12 Oct 2022 //
GLOBENEWSWIRE
Erasca to Present at the Bank of America Securities Precision Oncology
26 Sep 2022 //
GLOBENEWSWIRE
Erasca shores up case for testing its two lead candidates in combo
09 Sep 2022 //
ENDPTS
Erasca to Present at the Morgan Stanley Global Healthcare Conference
09 Sep 2022 //
GLOBENEWSWIRE
Erasca Presents Promising Preliminary Phase 1/1b Monotherapy Data for ERAS-007
07 Sep 2022 //
GLOBENEWSWIRE
